Table 4. Efficacy data from the approval and update trials of the targeted drugs for renal cell carcinoma.
| Treatment / control | Prior treatment | Median PFS (months) | Median overall survival (months) |
|---|---|---|---|
| Sorafenib Placebo |
none | 5.5 2.8 |
19.3 15.9 (p=0.02) |
| Sunitinib IFN-alpha |
none | 11 5 |
26.4 21.8 (p=0.051) |
| Pazopanib Placebo |
none or cytokines | 9.2 4.2 |
22.9 20.5 (p=0.224) |
| Pazopanib Sunitinib |
none | 8.4 9.5 |
28.4 29.3 (p=0.28) |
| Bevacizumab + IFN-alpha Placebo + IFN-alpha |
none | 10.2 5.4 |
23.3 21.3 (p=0.336) |
| Temsirolimus* Temsirolimus + IFN-alpha IFN-alpha |
none | 5.5 4.7 3.1 |
10.9 8.4 7.3 (p=0.008 for temsirolimus vs. IFN-alpha) |
| Axitinib Sorafenib |
VEGF inhibitor or cytokines | 6.7 4.7 |
20.1 19.2 (p=0.374) |
| Everolimus Placebo |
VEGF inhibitor | 4.9 1.9 |
14.8 14.4 (p=0.162) |
*in patients with an unfavorable risk profile IFN-alpha. interferon-alpha; p. singifiance value; PFS. progression-free survival; VEGF. vascular endothelial growth factor; vs.. versus